Lite Strategy, Inc. Common Stock (LITS) Stock Price

LITSStock

$1.05−79.28%52W

Market Cap$35.73M

P/E—

PEG Ratio2.22

Div yield—

Beta0.11

LITS Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-17.61%

Price vs S&P 500 (4W)3.13%

PEG Ratio2.22

VGM Score55.86

Book Value / Share (Quarterly)$1.62

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-0.30

Price vs S&P 500 (YTD)-33.93%

Gross Margin (TTM)100.00%

Net Profit Margin (TTM)39.05%

EPS (TTM)$-1.74

10-Day Avg Trading Volume0.15M

EPS Excl Extra (TTM)$-1.74

EPS (Annual)$-2.39

Dividend / Share (Annual)$0.00

ROI (Annual)-94.18%

Gross Margin (Annual)100.00%

Net Profit Margin (5Y Avg)-92.08%

Cash / Share (Quarterly)$0.27

ROA (Last FY)-87.20%

EBITD / Share (TTM)$-1.96

ROE (5Y Avg)-71.43%

Operating Margin (TTM)34.86%

Cash Flow / Share (Annual)$-3.13

P/B Ratio0.53x

P/B Ratio (Quarterly)0.74x

Net Income / Employee (Annual)$-3,986,300

Net Interest Coverage (TTM)-21.51x

ROA (TTM)-67.48%

EPS Incl Extra (Annual)$-2.39

Current Ratio (Annual)13.50x

Quick Ratio (Quarterly)10.11x

3-Month Avg Trading Volume0.32M

52-Week Price Return-79.28%

Revenue / Employee (TTM)$0

P/S Ratio (Annual)0.47x

Asset Turnover (Annual)1.58x

52-Week High$5.50

Operating Margin (5Y Avg)-100.94%

EPS Excl Extra (Annual)$-2.39

26-Week Price Return-6.36%

Quick Ratio (Annual)13.30x

13-Week Price Return-6.36%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)11.53x

Enterprise Value$22.83M

Asset Turnover (TTM)0.84x

Revenue / Employee (Annual)$0

Pretax Margin (Annual)27.23%

Cash / Share (Annual)$2.70

3-Month Return Std Dev75.95%

Gross Margin (5Y Avg)38.18%

Net Income / Employee (TTM)$-9,924,800

ROE (Last FY)-94.18%

EPS Basic Excl Extra (Annual)$-2.39

P/FCF (TTM)0.42x

Receivables Turnover (TTM)1306.00x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-1.74

Receivables Turnover (Annual)1305.94x

ROI (TTM)-68.86%

P/S Ratio (TTM)0.29x

Pretax Margin (5Y Avg)-92.08%

Revenue / Share (Annual)$0.00

Price vs S&P 500 (52W)-97.59%

Year-to-Date Return-21.97%

5-Day Price Return16.78%

EPS Normalized (Annual)$-2.39

ROA (5Y Avg)-24.99%

Net Profit Margin (Annual)27.23%

Month-to-Date Return6.90%

EBITD / Share (Annual)$-2.56

Operating Margin (Annual)22.27%

ROI (5Y Avg)-71.43%

EPS Basic Excl Extra (TTM)$-1.74

Payout Ratio (Annual)65.59%

P/B Ratio (Annual)0.97x

Dividend / Share (TTM)$0.00

Pretax Margin (TTM)39.05%

Book Value / Share (Annual)$2.54

Price vs S&P 500 (13W)-9.16%

Dividend Yield (TTM)0.00%

Beta0.11x

P/FCF (Annual)0.91x

Revenue / Share (TTM)$0.00

ROE (TTM)-68.86%

52-Week Low$0.69

vGradeB

mGradeC

vgmGradeC

LITS Earnings Surprise History

Q3 238.46est. -1.79

Q4 23-1.66est. -1.27

Q1 24-1.37est. -1.26

Q2 24-1.13est. -1.40

LITS Analyst Recommendations

Aug 2025

Sep 2025

Oct 2025

Nov 2025

2.17

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
LITSLite Strategy, Inc. Common Stock	B	—	C	$1.05
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About Lite Strategy, Inc. Common Stock

Lite Strategy Inc is a clinical-stage pharmaceutical company developing novel therapies for cancer. The company's pipeline includes voruciclib, an oral CDK9 inhibitor, and zandelisib, an oral PI3K inhibitor, both designed to improve patient outcomes in oncology.